OpenEvidence
Coverage of OpenEvidence in the Nexus archive.
- STAT+: A sweeping new AI to detect heart conditions is coming to OpenEvidence
EchoNext, an AI model developed by New York-Presbyterian Hospital researchers and commercialized by Pathway Labs, has received FDA clearance to detect seven forms of structural heart disease from EKGs. Pathway Labs will license the technology to OpenEvidence, a medical evidence search engine used by hundreds of thousands of clinicians.
- STAT+: OpenEvidence makes its pitch to hospitals. ‘We’re not crazy monsters’
OpenEvidence has built a free chatbot for doctors and achieved a $12 billion valuation in four years, with about 650,000 U.S. physicians using it actively. The company is now facing competitive pressures and questions about its ad-based business model. OpenEvidence is aiming to expand its reach to hospitals.
- STAT+: Dexcom CEO hints at future uses for CGM
Dexcom CEO hints at future uses for CGM, and the author is attending the STAT Breakthrough Summit West in San Francisco. The summit features interviews with key figures like OpenEvidence CTO Zachary Ziegler. Readers can follow coverage on Statnews.com and social channels.
- Most U.S. doctors are quietly using this AI tool. Few patients know about it.
Most U.S. doctors are using OpenEvidence, an AI tool, to inform their medical decision-making, with few patients aware of its use. This tool is being utilized by a significant majority of doctors in the U.S. The use of OpenEvidence is intended to support medical decisions.
- STAT+: Did AI really beat doctors at diagnosis?
The article discusses the STAT Health Tech newsletter and its upcoming Breakthrough Summit West in San Francisco, featuring an interview with OpenEvidence co-founder Zachary Ziegler. The summit will explore how technology is transforming life sciences. Registration is still open.